Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
The investigators design a phase IIB clinical study to explore the efficacy and safety of Donafenib combined with TACE as adjuvant therapy of patients with hepatocellular carcinoma at a high risk of recurrence after radical resection.
Hepatocellular Carcinoma
DRUG: Donafenib
1 year RFS rate, 1 year relapse-free survival rate, 1 year
RFS, Recurrence Free Survival, 3 years|OS, Overall Survival, 3 years|TTR, Time To Recurrence, 3 years|2/3 year RFS rate, 2/3 year Recurrence free survival rate, 2/3 years|AE, Adverse events, 3 years|AFP, Alpha fetal protein, 3 years
This trial is a single-arm, non-randomized and single-center clinical study of targeted therapy combined TACE in patients with hepatocellular carcinoma at a high risk of recurrence after radical resection.It is estimated that 30 patients who met the study criteria will be enrolled in Peking Union Medical College Hospital(PUMCH) and treated with Donafenib and TACE. The investigators will follow up and collect subjects' data monthly to evaluate the efficacy and safety of treatment, including overall survival and time to progression.